The EPS beat and pipeline catalysts support near-term momentum. Monitor Halneuron Phase 2b data in fall 2026 and partnership payments. Cash runway is sufficient through 2026, but dilution risk remains if additional financing is needed.
Price Chart
Executive Summary
Dogwood Therapeutics reported Q1 2026 EPS of -$0.15, beating consensus of -$0.20 by 25%, with no revenue. The company highlighted pipeline progress (Halneuron Phase 2b on track for fall 2026, SP16 IND clearance) and a potential $100M partnership for legacy antiviral assets. Cash runway extends into Q4 2026.
Key Financial Metrics
Key Facts
- EPS -$0.15 vs consensus -$0.20 (25% beat)
- Net loss $5.0M vs $12.2M in Q1 2025
- Cash and equivalents $13.2M, runway into Q4 2026
- Halneuron Phase 2b CINP study fully enrolled (164 patients); top-line results expected fall 2026
- SP16 IND accepted for CIPPN; Phase 1b fully funded by NCI
- Executed global development license for legacy antiviral assets with potential value up to $100M
Financial Impact
EPS beat of $0.05 per share; no revenue; partnership could yield up to $100M in milestones
Risk Factors
- Pre-revenue stage with ongoing R&D expenses
- Clinical trial risk for Halneuron and SP16
- Cash runway limited to Q4 2026; potential need for future financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294918 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | SC 13D/A | $1.12 | awaiting T+60 | — | $1.13 (+0.89%) |
Oct 19, 2026 7d ago | 8-K | $1.21 | awaiting T+60 | — | $1.13 (−6.61%) |
Oct 19, 2026 7d ago | Press Release | $1.21 | awaiting T+60 | — | $1.13 (−6.61%) |
Aug 13, 2026 10w ago | 8-K | $1.98 | awaiting T+60 | — | $1.13 (+42.93%) |
May 18, 2026 23w ago | Press Release | $1.70 $1.93 | ▲ +13.24% | ▲ +8.38% | $1.13 (−33.53%) |
May 14, 2026 23w ago | 8-K | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.13 (−42.93%) |
May 14, 2026 23w ago | Press Release | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.13 (−42.93%) |
Apr 15, 2026 27w ago | Press Release | $1.71 $1.42 | ▼ −16.96% | ▼ −25.10% | $1.13 (−33.92%) |
Mar 18, 2026 31w ago | Press Release | $2.97 $1.57 | ▼ −47.14% | ▼ −58.66% | $1.13 (−61.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers